University of Kentucky

UKnowledge
Pharmaceutical Sciences Faculty Patents

Pharmaceutical Sciences

3-9-2004

2,6-Disubstituted Piperidines as Modulators of Nicotinic
Acetylcholine Receptor Mediated Neurotransmitter Release,
Uptake and Storage
Peter A. Crooks
University of Kentucky, pcrooks@uky.edu

Linda P. Dwoskin
University of Kentucky, ldwoskin@email.uky.edu

Dennis Keith Miller
University of Kentucky

Vladimir P. Grinevich
University of Kentucky

Seth Davin Norrholm
University of Kentucky
Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
See next page for additional authors
Part of the Pharmacy and Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.
Recommended Citation
Crooks, Peter A.; Dwoskin, Linda P.; Miller, Dennis Keith; Grinevich, Vladimir P.; Norrholm, Seth Davin; and
Zheng, Guangrong, "2,6-Disubstituted Piperidines as Modulators of Nicotinic Acetylcholine Receptor
Mediated Neurotransmitter Release, Uptake and Storage" (2004). Pharmaceutical Sciences Faculty
Patents. 70.
https://uknowledge.uky.edu/ps_patents/70

This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been
accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge.
For more information, please contact UKnowledge@lsv.uky.edu.

Authors
Peter A. Crooks, Linda P. Dwoskin, Dennis Keith Miller, Vladimir P. Grinevich, Seth Davin Norrholm, and
Guangrong Zheng

This patent is available at UKnowledge: https://uknowledge.uky.edu/ps_patents/70

US006703406B2

(12) United States Patent

(10) Patent N0.:
(45) Date of Patent:

Crooks et al.

(54) 2,6-DISUBSTITUTED PIPERIDINES AS
MODULATORS OF NICOTINIC
ACETYLCHOLINE RECEPTOR MEDIATED

NEUROTRANSMITTER RELEASE, UPTAKE
AND STORAGE

(75) Inventors: Peter A. Crooks, Lexington, KY (US);
Linda Dwoskin, Lexington, KY (US);
Dennis Keith Miller, Lexington, KY
(US); Vladimir P. Grinevich,
Lexington, KY (US); Seth Davin

Norrholm, Lexington, KY (US);
Guangrong Zheng, Lexington, KY

(Us)

US 6,703,406 B2
Mar. 9, 2004

Y. Cheng et al. “Relationship between the inhibition con
stant (K1) and the concentration of inhibitor which casuses
50 per cent inhibition (I50) of an enzymatic reaction” Bio
chemical Pharmacology. vol. 22. No. 23. Dec. 1, 1973.
3099—3108.
Michael Decker et al. “Effects of Lobeline, a Nicotinic

Receptor Agonist, on Learning and Memory” Pharmacology
Biochemistry and Behavior. vol. 45. 1993. 571—576.
Carmelo Romano et al. “Stereospeci?c Nicotine Receptors
on Rat Brain Membranes” Science. vol. 210. Nov. 7, 1980.
647—650.

S. Hamann et al. “Hyperalgesic and Analgesic Actions of

Morphine, U50—488, Naltrexone, and (—)—Lobeline in the
Rat Brainstem” Pharmacology Biochemistry and Behavior.

(73) Assignee: University of Kentucky Research
Foundation, Lexington, KY (US)

vol. 47. 1993. 197—201.

(*)

Subject to any disclaimer, the term of this
patent is extended or adjusted under 35

[3H]dopamine over?ow from rat striatal slices and nicoti

U.S.C. 154(b) by 0 days.

Neuropharmacology. 2000. 39:2654—2662.
Patrick M. Lippiello et al. “The Binding of L—[3H] Nicotine

Notice:

(21) Appl. No.: 10/163,633
(22) Filed:
(65)

Jun. 7, 2002
Prior Publication Data

peutics. 1996. vol. 239. No. 2. 442—453.
M. Marks et al. “Nicotonic Binding Sites in Rat and Mouse

Related US. Application Data
Continuation-in-part of application No. 09/628,557, ?led on
Jul. 28, 2001, now Pat. No. 6,455,543.

(60)

Provisional application No. 60/146,144, ?led on Jul. 30,
1999.

(51)

ne—evoked 86 Rb+ ef?ux from thalamic synaptosomes”

to a Single Class of High Af?nity Sites in Rat Brain
Membranes” Molecular Pharmacology. 29:448—454.
L. Dwoskin et al. “Robust Modulation of [3H] Dopamine
Release from Rat Striatal Slices by D—2 Dopamine Recep
tors” The Journal of Pharmacology and Experimental Thera

US 2004/0019081 A1 Jan. 29, 2004

(63)

Dennis K. Miller et al. “Lobeline inhibits nicotine—evoked

Brain: Comparison of Acetylcholine, Nicotine, and ot—Bun
garotoxin” Molecular Pharmacology. 30:427—436.
E. Broussolle et al. “In Vivo Speci?c Binding of [3H]
1—Nicotine in the Mouse Brain” Life Sciences. 1989. vol.
44. 1123—1132.

Int. Cl.7 .................. .. A61K 31/445; C07D 211/18;

C07D 211/20
(52)

us. Cl. ..................... .. 514/317; 514/331; 546/192;

546/229
(58)

Field of Search ............................... .. 514/317, 331;

546/192, 229

(56)

References Cited
U.S. PATENT DOCUMENTS
6,455,543 B1 *

(List continued on next page.)

Primary Examiner—Rita Desai
(74) Attorney, Agent, or Firm—McDermott, Will & Emery

(57)

ABSTRACT

Compounds used for treating dependence on or withdrawal
from a drug of abuse, for an eating disorder or for a CNS

disease or pathology having the following formulas:

9/2002 Dwoskin et al. .......... .. 514/317

OTHER PUBLICATIONS

P. Crooks et al. “Inhibition of Nicotine Evoked [3H]Dopam

ine Release by Pyridino N—Substituted Nicotine Analogues:
A New Class of Nicotinic Antagonist” Drug Development

CH3

Research. 1995. 36:91—102.

L. Teng et al. “Lobeline Displaces [3H] Dihydrotetrabena
Zine Binding and Release [3H] Dopamine from Rat Striatal

and

Synaptic Vesicles: Comparison with d—Amphetamine” J our
nal of Neurochemistry. vol. 71. No. 1. Jul. 1998. 258—265.
L. Teng et al. “Lobeline and Nicotine Evoke [3H] Over?ow
from Rat Striatal Slices Preloaded with [3H] Dopamine:

Differential Inhibition of Synaptosomal and Vesicular [3H]
Domapine Uptake” The Journal of Pharmacology and
Experimental Therapeutics. Williams & Wilkins. vol. 280.
No. 3. 1997. 1432—1444.

CH3

9 Claims, No Drawings

US 6,703,406 B2
Page 2

OTHER PUBLICATIONS

L. DWoskin et al. “(S)—(—)—Cotinine, the Major Brain
Metabolite of Nicotine, Stimulates Nicotonic Receptors to
Evoke [3H] Dopamine from Rat Striatal Slices in Calcium—
Dependent Manner” The Journal of Pharmacology and
Experimental Therapeutics. 1999. vol. 288. No. 2. 905—911.
R.B. BarloW et al. “Relations betWeen structure and nicoti

ne—like activity: X—ray crystal structure analysis of
(—)—cytisine and (—)—lobeline hydrochloride and a compari
son With (—)—nicotine and other nicotine—like compounds”
Br. Journal of Pharmacology. 1989. vol. 98. 799—808.

P.B.S. Clark & M. Reuben. “Release of [3H]—noradrenaline
from rat hippocampal synaptosomes by nicotine: mediation

by different nicotinic receptor subtypes from striatal [3H]—
dopamine release” British Journal of Pharmacology. 1996.
117. 595—606.

M. Bradford, “A Rapid and Sensitive Method for the Quan
titation of Micogram Quantities of Protein UtiliZing the

Principle of Protein—Dye Binding” Analytical Biochemistry.
1976. 72. 248—254.
* cited by examiner

US 6,703,406 B2
1

2

2,6-DISUBSTITUTED PIPERIDINES AS

acts With postsynaptic receptors and subsequently is taken
back up into the terminal via the plasma membrane trans

MODULATORS OF NICOTINIC
ACETYLCHOLINE RECEPTOR MEDIATED

porter (e.g., the dopamine transporter, DAT and/or the

NEUROTRANSMITTER RELEASE, UPTAKE

modify the concentration of neurotransmitter in the cytosolic

serotonin transporter, SERT). Thus, transporter proteins

AND STORAGE

and vesicular storage pools, thereby having the ability to
alter subsequent neurotransmission.

RELATED APPLICATIONS

This application is a continuation-in-part of application
Ser. No. 09/628,557 ?led Jul. 28, 2000 now US. Pat. No.

6,455,543 Which claims priority under 35 U.S.C. § 119(e)(1)
to provisional Application No. 60/146,144 ?led Jul. 30,

10

1999.
FIELD OF INVENTION
15

The present invention relates to the use of the 2,6

drug effective to reduce an individual’s desire for a drug of
abuse or for food, or for alleviating at least one of the
symptoms of the disease or pathological symptom of CNS

and trans-2,6-di-trans-styrylpiperidine, as modulators of

nicotinic acetyl-choline receptor mediated neurotransmitter

release, uptake and storage. The 2,6-disubstituted pip

20

tered subcutaneously, intramuscularly, intravenously,
25

ment of therapeutic agents for a Wide variety of central
30

neuroendocrine, neuropsychiatric and neurological diseases,
memory and learning disabilities, eating disorders, and the

means of modulating nicotinic receptor function. Nicotinic

In a preferred aspect of the invention, the method of
35

agonists rapidly desensitiZe these receptors, essentially

40

agonists are currently being developed. For example, schiZo

45

selective nicotinic receptor antagonists Will be invaluable
agents in both basic and clinical research, With regard to
both the treatment and diagnosis of disease. Finally,
subtype-selective antagonists Will de?ne the role of speci?c
nicotinic receptor subtypes in both physiological function

ness and depression, and related conditions are considered to

cis-2,6-di-trans-styrylpiperidine and trans-2,6-di-trans

nephrine (NE) and serotonin (5-HT) release, uptake and
55

vesicles, Which are prominent features of nerve terminals.
Concentration into vesicles appears to be responsible for

styrylpiperidine are found to be effective in inhibiting uptake
of extracellular 5-HT by serotonergic nerve terminals in the
CNS, as Well as in inhibiting the binding of [3H]MTBZ to
vesicle membranes indicating an interaction With VMAT2.
These analogs are also nicotinic receptor antagonists, inhib

iting nicotine-evoked [3H]DA and [3H]NE release from rat

maintaining a ready supply of neurotransmitter available for
neuronal exocytotic release into the synaptic cleft. Vesicles

brain slices. Either or both mechanisms can thereby alter the
60

distribution of the intracellular neurotransmitter pools, and
as a result, alter extracellular neurotransmitter concentra

tions.
DETAILED DESCRIPTION OF THE
INVENTION

cytosol into the synaptic vesicle. MethoxytetrabenaZine
(MTBZ) has been used as a radiolabel to probe the interac
tion of drugs With VMAT2. Once the neurotransmitter is
released from the terminal into the synaptic space, it inter

disorders, obsessive compulsive disorders, panic disorders,
myasthenia gravis, Parkinson’s disease, AlZheimer’s
disease, schiZophrenia, Tourette’s syndrome, Huntington’s
disease, attention de?cit disorder, hyperkinetic syndrome,
be susceptible to treatment With a compound of the present
invention.
As shoWn by the results of the studies described herein,

The action of many neuropharmacologically therapeutic
agents involve the modulation of dopamine (DA), norepi

also serve the role of protecting the neurotransmitter from
metabolic breakdown. One transport site on the vesicle
membrane is the vesicular monoamine transporter-2
(VMAT2), Whose role is to transport transmitter from the

draWal and for eating disorders, other uses are also sug

chronic nervous exhaustion, narcolepsy, pain, motion sick

and disease states.

storage Within its respective terminals in the central nervous
system (CNS). Most neurotransmitters are stored in synaptic

plated primarily for the treatment of drug abuse and With

gested by the studies discussed herein. Thus, cognitive
disorders, brain trauma, memory loss, psychosis, sleep

phrenia and drug abuse have both been associated With
hyperactivity of CNS dopaminergic systems, and inhibition
of nicotinic receptors may be advantageous in reducing such

hyperactivity. Furthermore, the availability of subtype

treatment reduces an individual’s desire for the drug of
abuse or for food by at least one day, but it is also preferred

that the treatment method further comprises administering
behavior modi?cation counseling to the individual.
Although the compound of the present invention is contem

inhibiting their function. Thus, inhibition of nicotinic recep
tor function may be the action, Which confers clinical utility,
indicating that nicotinic receptor antagonists could also be
bene?cial in the treatment of diseases for Which nicotinic

cocaine, amphetamine, caffeine, nicotine, phencyclidine,
opiates, barbiturates, benZodiaZepines, cannabinoids,
hallucinogens, and alcohol is implicated. Also, the treatment
of eating disorders such as obesity is implicated.

control of pain, as Well as cardiovascular and gastrointesti

nal disorders. Nicotinic receptor antagonists have good
potential as therapeutic agents, since they offer another

transdermally, orally, intranasally, intrapulmonary or rec
tally. The use of cis-2,6-di-trans-styrylpiperidine or trans-2,
6-di-trans-styrylpiperidine and derivatives thereof in treat
ing diseases or pathologies of the CNS is implicated. In
particular, the treatment of dependencies on such drugs as

Currently, drug discovery is focusing on neuronal nico
tinic receptors (nAChRs) as novel targets for the develop

nervous system (CNS) diseases including, drug addiction,

pathology.
The compound can be administered alone, combined With
an excipient, or co-administered With a second drug having
a similar or synergistic effect. The compound is adminis

neuropathologies.
BACKGROUND OF THE INVENTION

cis-2,6-di-trans-styrylpiperidine or trans-2,6-di-trans
styrylpiperidine or an analog thereof, including pharmaceu
tically acceptable salts of such compounds thereof. As used
Wherein, the term “effective amount” means an amount of a

disubstituted piperidines, cis-2,6-di-trans-styrylpiperidine

eridines of the present invention can be used for the treat
ment of drug abuse and WithdraWal therefrom, as Well as for
the treatment of eating disorders such as obesity, and other

SUMMARY OF THE INVENTION
The present invention is directed to a method of treating
an individual Who suffers from drug dependence or With
draWal from drug dependence or Who suffers from a disease
or pathology of the CNS. The method comprises of admin
istering to the individual an effective amount of either

65

The 2,6-disubstituted piperidine analogs of the present
invention include those contemplated by the folloWing for
mula (I), Without regard to chirality:
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4
phosphates, carbonates, citrates and the like. Exemplary
preservatives include EDTA, EGTA, BHA, BHT and the

(1)
R3

like. Acomposition of the invention may be administered by
inhalation, i.e., intranasally as an aerosol or nasal formula
tion; topically, i.e., in the form of an ointment, cream or

/

lotion; orally, i.e., in solid or liquid form (tablet, gel cap,
time release capsule, powder, solution, or suspension in
aqueous or non aqueous liquid; intravenously as an infusion
or injection, i.e., as a solution, suspension or emulsion in a

wherein:

10

pharmaceutically acceptable carrier; transdermally, e.g., via

R1 represents a hydrogen, methyl, deuteromethyl (CD3),

a transdermal patch; rectally as a suppository and the like.

tritiomethyl (CT3), ethyl, or C3—C7 straight chain or

Generally, the pharmacologically effective dose of a
present compound is in the amount ranging from about
1><10_5 to about 1 mg/kg body weight/day. The amount to be

branched alkyl (preferably methyl or ethyl), C3—C6
cycloalkyl, vinyl, allyl, C4—C7 alkenyl (including cis and
trans geometrical forms), benZyl, and phenylethyl.

administered depends to some eXtent on the lipophilicity of
15

R2 and R3 are each independently ortho-, meta-, orpara

the speci?c compound selected, since it is eXpected that this

branched alkyl, C3—C6 cycloalkyl, vinyl, allyl, C4—C7 alk
enyl (including cis and trans geometrical forms), benZyl, and

property of the compound will cause it to partition into fat
deposits of the subject. The precise amount to be adminis
tered can be determined by the skilled practitioner in view
of desired dosages, side effects and medical history of the

phenylethyl. Further, the substitute moieties can be

patient and the like.

N-methylamino, N,N-dimethylamino, carboXylate,
methylcarboXylate, ethylcarboXylate, propylcarboXylate,
isopropylcarboXylate, carboXaldehyde, acetoXy,

invention exhibit activity at either nAChRs and/or the sero

substituted moieties, where the substituent is described as

hydrogen, methyl, ethyl, or C3—C7 straight chain or

The 2,6-disubstituted piperidino analogs of the present
tonin transporter protein (SERT) and/or the vesicular
monoamine transporter (VMATZ).

propionyloXy, isopropionyloXy, cyano, aminomethyl,

N-methylaminomethyl, N,N-dimethylaminomethyl,

25

carboXamide, N-methylcarboXamide, N,N

Compound 1

dimethylcarboXamide, acetyl, propionyl, formyl, benZoyl,

sulfate, methylsulfate, hydroXyl, methoXy, ethoXy, propoXy,
isopropoXy, thiol, methylthio, ethylthio, propiothiol, ?uoro,
chloro, bromo, iodo, tri?uoromethyl, propargyl, nitro,
carbamoyl, ureido, aZido, isocyanate, thioisocyanate,

\ \\““‘v

hydroXylamino, and nitroso.
The above 2,6-substituted piperidino analogs are pre
ferred in their 2,6-cis geometrical isomeric forms, or in their

N

"ll'lll/

CH3

Cis-Z,6-di-trans-styrylpiperidine

2,6-trans geometric forms, including all possible geometric,

35

racemic, diasteriomeric, and enantiomeric forms thereof.

Compound 2

The above 2,6-disubstituted piperidines as well as their
analogs can be administered in their free base form or as a
soluble salt. Whenever it is desired to employ a salt of a

2,6-substituted piperidine or its analog, it is preferred that a
soluble salt be employed. Some preferred salts include

N

hydrochloride, hydrobromide, nitrate, sulfate, phosphate,
tartrate, galactarate, fumarate, citrate, maleate, glycolate,
malate, ascorbate, lactate, aspartate, glutamate,
methanesulfonate, p-toluenesulfonate, benZenesulfonate,

CH3

Trans—2,6—di—trans-styrylpiperidine

salicylate, proprionate, and succinate salts. The above salt
Table 1 below summariZes the interaction of cis-2,6-di

forms may be in some cases hydrates or solvates with

trans-styrylpiperidine (Compound 1) and trans-2,6-di-trans
styrylpiperidine (Compound 2) with nicotinic receptors,

alcohols and other solvents.

Apharmaceutical composition containing a compound of

SERT and VMAT2.

the invention is also contemplated, which may include a

TABLE 1
Inhibition
Nicotine-

[3H]Nicotine [3H]MLA Evoked 86RB+

Binding

Binding

E?lux“
(ICSU)

Inhibition of

Inhibition of

Nicotine-

Nicotine-

Inhibition of

Evoked[3H]DA Evoked[3H]NE
[3H]MTBZ
Over?ow b(ICSU) Over?ow b(ICSO) binding (ICSU)

[3H]5—HT

Uptake
(ICSU)

Compound

(1452*

(17*

(1452*

(1352*

(1354*

vMAT2

SERT

1
2

11 ,uM
13 ,uM

>100 ,uM
>100 ,uM

>10 ,uM
Not

0.03 ,uM
0.54 ,uM

0.021
Not

1.29 ,uM
5.15 ,uM

23.2 ,uM
1.19 ,uM

determined

determined

3Inhibition of 1 ,uM S(—)—nicotine
bInhibition of 10 ,uM S(—)—nicotine

conventional additive, such as a stabiliZer, buffer, salt,
preservative, ?ller, ?avor enhancer and the like, as known to
those skilled in the art. Representative buffers include

65

The two 2,6-disubstituted piperidino derivatives in Table
1 have the chemical structure of Formula I, and were

assayed for interaction with 0146*, 017*, (x3[32*and

US 6,703,406 B2
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6

(x3[34*subtypes of nAChRs, interaction With VMAT2

-continued

located on vesicle membranes and inhibition of SERT func

OH O

tion. It shall be noted that the nAChR subtypes for the
activities described herein have not been elucidated
conclusively, and thus, the asterisk is an indication of the

OH

CH3

putative nature of the receptor subtype mediating the action.
Lobelanidine

Compound 1 exhibits good selectivity (43-fold) for the
(x3[32*subtype of nAChR relative to its interaction With the
MTBZ site on VMAT2, as indicated by its ability to inhibit

nicotine-evoked [3H]DA release. Moreover, Compound 1
exhibits very good selectivity (>370-fold) for the (x3[32*and
(x3[34*subtypes of nAChRs compared to its interaction With

CH3

either (x4[32*or ot7*subtypes of nAChR. Furthermore, Com
pound 1 Was 770-fold more selective as an inhibitor of the 15

Cis-2,6-di-trans-styrylpiperidine

(x3[32*and (x3[34*subtypes of nAChR compared to its inhi
bition of SERT function. Finally, Compound 1 interacted
With VMAT2 18-fold more selectively than it inhibited the
function of SERT.
Compound 2 Was also assayed for interaction With
nAChRs subtypes, interaction With VMAT2 located on
vesicle membranes and inhibition of SERT function. Com

20

CH3

Trans-2,6-di-trans-styrylpiperidine

pound 2 exhibits good selectivity (9.5-fold) for the
(x3[32*subtype of nAChR relative to its interaction With the
MTBZ site on VMAT2, as indicated by its ability to inhibit

25

portionWise at 0° C. The mixture Was stirred at 0° C. for 1
h, and then quenched With acetone. The mixture Was evapo

type of nAChR compared to its interaction With either

(x4[32*or ot7*subtypes of nAChR. Furthermore, Compound
2 Was only 2.2-fold more selective as an inhibitor of the

rated under reduced pressure. Water (100 mL) Was added to
30

evaporated to afford lobelanidine as a White solid Which Was

used directly. An analytical sample Was recrystalliZed from
acetone/hexane as a needle crystal. Mp 142—143° C; 1H
35

nicotine-evoked [3H]DA and [3H]NE release from rat stri
atal and hippocampal slices, indicated a higher affinity for
the (x3[32*and (x3[34*subtypes of nAChRs, compared to
40

Compound 1. Finally, Compound 1 Was only 4-fold more
potent interacting With VMAT2 compared to Compound 2.
Thus, alteration of stereochemistry at C2 and C6 from cis to
trans resulted in a diminished affinity for the (x3[32*subtypes
of nAChR and for VMAT2, and enhanced the affinity for
SERT, Whereas there Was no change in affinity for either

NMR (300 MHZ, CDCl3) 6 1.15 (m, 2H), 1.44—1.82 (m,
6H), 2.04 (ddd, J=14.4, 10.2, 8.7 HZ, 2H), 2.35 (s, 3H), 2.96
(m, 2H), 4.89 (dd, J=8.7, 5.5 HZ, 2H), 7.23—7.50 (m, 10H);
13C NMR (75 MHZ, CDCl3) 6 23.48, 25.20, 25.96, 41.79,
62.37, 74.30, 125.98, 127.50, 128.55, 144.88 ppm.

Compound 2. On the other hand, Compound 2 Was 19-fold
more potent inhibiting the function of SERT than Was

the residue and extracted With chloroform (80 mL><3). The
combined organic extract Was dried (MgSO4), ?ltered and

(x3[32*subtypes of nAChR compared to its inhibition of
SERT function. Finally, Compound 2 interacted With SERT
43-fold more selectively than it interacted With VMAT2.
Compound 1 Was 18-fold more potent at inhibiting

To a suspension of L-lobeline hemisulfate salt (85%, 10.5

g) in absolute ethanol (300 mL) Was added NaBH4 (1.5 eq.)

nicotine-evoked [3H]DA release. Moreover, Compound 2
exhibits very good selectivity (>24-fold) for the (x3[32*sub

Crude lobelanidine Was dissolved in 130 mL 85% H3PO4
and alloWed to stir at 60° C. for 24 h. The reaction mixture
Was cooled to room temperature, diluted With 250 mL Water

45

and made basic With solid NaOH (pH~10). The aqueous
solution Was extracted With EtOAc (150 mL><3) The com
bined organic extract Was dried (MgSO4), ?ltered and con
centrated under reduced pressure. The crude product Was

recrystalliZed from acetone affording 2.2 g of pure cis-2,6

(x4[32*or ot7*subtypes of nAR. Therefore, cis-analogs have
higher affinity for VMAT2 and (x3[32*subtype of nAChRs.

di-trans-styrylpiperidine as a White solid. Mp: 105—106° C.

(HCl salt); 1H NMR (300 MHZ, CDCl3) 6 1.42—1.88 (m,
6H), 2.25 (s, 3H), 2.63 (m, 2H), 6.21 (dd, J=15.9, 9.0, 2H),
6.51 (d, J=15.9, 2H), 7.19—7.41 (m, 10H); 13C NMR (75
MHZ, CDCl3) 6 24.14, 33.94, 42.61, 68.56, 126.32, 127.46,

The invention Will noW be discussed by certain examples
Which illustrate but do not limit the invention.
EXAMPLE 1

128.69, 130.51, 134.03, 137.17 ppm. The remaining mother
liquor Was evaporated and the residue Was chromatographed

Scheme 1: Synthesis of cis- and trans-2,6-di-trans-styrylpiperidine
Preparation of Cis- and trans-2,6-di-trans-styrylpiperidine

OH

55

NaBH4

(m, 2H), 2.27 (s, 3H), 3.38 (m, 2H), 6.38 (dd, J=15.9, 8.7,
2H), 6.52 (d, J=15.9, 2H), 7.17—7.42 (m, 10H); 13C NMR
(75 MHZ, CDCl3) 6 19.57, 32.92, 41.96, 62.29, 126.39,

ethanol

127.50, 128.69, 130.49, 131.78, 137.20 ppm.

0
‘_.~

\\\\

N

-.,I

I

1,1!

(SiO2, EtOAc/hexanes, 1/10) to afford cis-2,6-di-trans
styrylpiperidine 1.4g and trans-2S,6S-di-trans
styrylpiperidine 230 mg. Mp: 200—202° C. (HCl salt); 1H
NMR (300 MHZ, CDCl3) 6 1.60—1.75 (m, 4H), 1.82—1.97

—>

CH3

EXAMPLE 2

1/2 H2504

High Affinity [3H]Nicotine Binding Assay

Lobeline

65

The ability to displace S(—)[3H]nicotine binding from rat
striatal membranes Which assessed the (x4[32*subtype Was

US 6,703,406 B2
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8

determined. The [3H]nicotine binding assay Was performed
according to previously published methods (Romano et al.,
1980; Marks et al., 1986; Crooks et al., 1995). Striata from

terminated by dilution of samples With 3 mL ice-cold
incubation buffer folloWed by immediate ?ltration through
Schleicher & Schuell #32 glass ?ber ?lters (Keene, NH;

presoaked With 0.5% PEI) using the cell harvester. Filters

tWo rats Were dissected, pooled and homogenized With a
Tekmar polytron in 10 vol of ice-cold modi?ed Krebs

Were rinsed 3 times With 3 mL of ice-cold buffer, transferred
to scintillation vials, 4 mL of scintillation cocktail added,

HEPES buffer (20 mM HEPES, 118 niM NaCl, 4.8 mM

KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, adjusted to pH to 7.5).

and bound radiolabel determined by liquid scintillation

The homogenate Was incubated at 37° C. for 5 min to

spectroscopy. Protein Was measured using the Bradford

promote hydrolysis of endogenous acetylcholine, and cen
trifuged at 27,000 g for 20 min and the pellet Was resus
pended in 10 vol of ice-cold distilled Water and incubated at

dye-binding method (Bradford, 1976) With BSA as the
10

standard.
EXAMPLE 4

37° C. for 5 min, folloWed by centrifugation at 27,000 g for
20 min. The pellet containing the striatal membranes Was
resuspended in 10 vol of fresh ice-cold 10% Krebs-HEPES

[3H]MethoxytetrabenaZine [3H]MTBZ Binding

buffer and incubated at 37° C. for 10 min after Which it Was 15

Assay

centrifuged at 27,000 g for 20 min. The latter sequence of

Synaptic vesicles Were prepared from rat brain using a

resuspension, incubation and centrifugation Was repeated.

modi?cation of a previously described procedure (Teng et

The pellet Was froZen under fresh Krebs-HEPES buffer and
stored at —40° C. until assay. Upon assay, the pellet Was
resuspended in Krebs-HEPES buffer, incubated at 37° C. for
5 min and centrifuged at 27,000 g for 20 min. The ?nal pellet
Was resuspended in 3.6 mL ice-cold Water, Which provides

al., 1998). Brie?y, fresh Whole brain (excluding cerebellum)
Was homogeniZed using a Te?on pestle (clearance 0.003
20

C. The resulting supernatant (S1) Was then centrifuged at
22,000 g for 10 min at 4° C. The synaptosomal pellets (P2)

for approximately 200 pg protein/100 pL aliquot, as de?ned

by the Bradford dye binding method (Bradford, 1976) using
bovine serum albumin (BSA) as the standard. Competition
assays Were performed in duplicate in a ?nal vol of 200 pL

mm) With 7 vertical strokes at 800 rpm in 20 vol of ice-cold
0.32 M sucrose and centrifuged at 1000 g for 12 min at 4°

Were homogeniZed in 18 mL of ice-cold Milli-Q Water and
25

exposed for 5 min for lysing synaptosomes. Osmolarity Was
restored by addition of 2 mL of 25 mM HEPES With 100

Krebs-HEPES buffer containing 250 mM Tris buffer (pH 7.5
at 4° C.). Reactions Were initiated by addition of 100 pL of

mM dipotassium tartrate (pH 7.5). Samples Were centrifuged

membrane suspension to 3 nM [3H]nicotine (L-(—)-[N

mal membranes. MgSO4 (1 mM) Was added to the super
natant (S3), and Was centrifuged at 100,000 g for 45 min at
4° C. The ?nal vesicular pellets (P4) Were resuspended in

methyl-3H]nicotine; 50 pL, speci?c activity 69.5 Ci/mMol)

at 20,000 g for 20 min at 4° C. to remove lysed synaptoso
30

and 1 of at least 9 concentrations of analog (50 ML). After a
90 min incubation at 4° C., reactions Were terminated by
dilution of the samples With 3 mL of ice-cold buffer folloWed

immediately by ?ltration through a Whatman GF/B glass
?ber ?lters (presoaked in 0.5% polyethyleneimine using a
Brandel cell harvester). Filters Were rinsed 3 times With 3
mL of ice-cold buffer, transferred to scintillation vials and 5
mL scintillation cocktail added. Nonspeci?c binding Was
de?ned as binding in the presence of 10 pM S(—)-nicotine.
For competition curves, the IC5O values Were corrected for
ligand concentration to obtain Ki values for each analog

ice-cold assay buffer (see beloW) providing ~15 pg protein/
100 ML, determined by the method of Bradford (1976) using
bovine serum albumin as a the standard. Aliquot parts (100
35

40

(Cheng et al., 1973).
EXAMPLE 3

[3H]Methyllycaconitine ([°]HIMLA)Binding Assay

?ltration of samples on a Uni?lter-96 GF/B ?lter plates
45

Washing 5 times With 350 ML of the ice-cold Wash buffer (25
mM HYEPES, 100 mM dipotassium tartrate, 5 mM MgSO4
and 10 mM NaCl, pH 7.5), ?lter plates Were dried, sealed
and each Well ?lled With 40 pL Packard’s MicroScint 20
cocktail. Bound [°H]MTBZ Was measured using a Packard
TopCount NXT scintillation counter With a Packard Win

at 4° C. Pellets Were Washed 3 times by resuspension in 20
vol of the same buffer and centrifugation using the above
parameters. Final pellets Were resuspended in incubation

doWs NT based operating system.
55

Were performed in duplicate, in a ?nal vol of 250 pL

EXAMPLE 5

[3H]5-HT Uptake Assay

incubation buffer, containing 20 mM HEPES, 144 mM
NaCl, 1.5 mM KCl, 2 mM CaCl2, 1 mM MgSO4 and 0.05%
BSA, pH 7.5. Assays Were initiated by the addition of 100

pL membrane suspension to 150 ML of sample containing 2.5

(presoaked in 0.5% polyethylenimine), using a FilterMate

harvester (Packard BioScience Co., Meriden, Conn.). After

Whole rat brain (minus cortex, striatum and cerebellum)
Was homogeniZed in 20 vol of ice-cold hypotonic buffer (2
mM HEPES, 14.4 mM NaCl, 0.15 mM KCl, 0.2 mM CaCl2
and 0.1 mM MgSO4, pH 7.5). Homogenates Were incubated
at 37° C. for 10 min and centrifuged at 25,000 g for 15 min

buffer to provide ~150 pg protein/100 pL. Binding assays

ML) of suspension of vesicle membrane protein Were incu
bated in assay buffer (25 mM HEPES, 100 mM dipotassium
tartrate, 5 mM MgSO4, 0.1 mM EDTA and 0.05 mM EGTA,
pH 7.5, at 25° C.) in the presence of 3 nM [°H]MTBZ
([O-methyl -°H]methoxytetrabenaZine) and at least 7 con
centrations (1 nM—1 mM) of analog for 1 hr at room
temperature. Nonspeci?c binding Was determined in the
presence of 20 pL TBZ. Assays Were performed in duplicate
using a 96-Well plate format. Reactions Were terminated by

[3H]5-HT uptake Was assessed using modi?cations of a

previously described method (Teng et al., 1998). Nonspe
60

nM [3H]MLA ([1ot, 4(S), 6B, 1401, 16[3]-20-ethyl-1,6,14,16

tetramethoxy-4[[[2-(-[3-3H]-methyl-2,5-dioxo-1

ci?c uptake Was determined in duplicate samples in the
presence of excess (10 pM) ?uoxetine. Rat hippocampus
Was homogeniZed in 20 mL cold 0.32 M sucrose containing

pyrrolidinyl)benZoyl]oxy]methyl]aconitane-7,8-diol; spe

5 mM NaHCO3 (pH 7.4) With 12 vertical strokes of a Te?on

ci?c activity 26.2 Ci/mMol) and at least 6 concentrations (30

pestle homogeniZer (clearance~0.015

nM—100 pM) synthetic analog (?nal concentrations), and
incubated for 2 h at room temperature. Nonspeci?c binding
Was determined in the presence of 10 pM MLA. Assays Were

65

The homoge

nate Was centrifuged (2,000><g for 10 min at 4° C.). The
supernatant Was centrifuged (20,000><g for 15 min at 4° C.),
and then the pellet Was resuspended in 1.5 mL of Kreb’s
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buffer (125 rnM NaCl, 5 rnM KCl, 1.5 rnM MgSO4, 1.25
rnM CaCl2, 1.5 rnM KH2PO4, 10 rnM ot-D-glucose, 25 rnM
HEPES, 0.1 rnM disodiurn ethylenediarnine tetraacetate, 0.1
rnM pargyline and 0.1 rnM ascorbic acid, saturated With
95% O2/5% CO2, pH 7.4). Final protein concentration Was
400 pg/rnL, determined using BSA standard (Bradford,

superfusate sarnples. Radioactivity in the superfusate and
tissue samples was determined by liquid scintillation spec
troscopy (Packard rnodel B1600 TR Scintillation Counter,

DoWner’s Grove, Ill.).
EXAMPLE 7

1976). The assay Was performed in duplicate in a total vol

86Rb+ Rubidiurn Ef?uX Assay

of 500 pL. Aliquot parts of synaptosornal suspension (50 ML)

Analog effects on 8° Rb+ efflux were determined using a

Were added to tubes containing 350 pL Kreb’s buffer and 50

pL of buffer containing 1 of 9 concentrations of analog.

10

previously published rnethod (Miller et al., 2000). Thalarnus

15

buffer (1.40 rnM NaCl, 1.5 rnM KCl, 2.0 rnM CaCl2, 1.0

Tubes Were preincubated at 34° C. for 10 min before

addition of 50 ML of [3H]5-HT (5-[1,2-3H(N)]
hydroXytryptarnine; speci?c activity 25.5 Ci/rnMol, ?nal
concentration 10 nM). Accurnulation proceeded for 10 min
at 34° C. Reactions were terminated by addition of 3 rnL

ice-cold Kreb’s buffer. Samples were rapidly ?ltered
through a Whatrnan GF/B ?lter using a cell harvester

(MP-43RS, Brandel Inc., Gaithersburg, Md.), and the ?lter
20

soaked for 2 hours in the ice-cold Kreb’s buffer containing
catechol (1 rnM). Radioactivity on ?lters was determined by

25

[3H]Doparnine and [3H]Norepineplhrine Release
Assay

synaptosornes at a rate of 2.5 rnL/rnin. TetrodotoXin and
CsCl Were included in the buffer to block voltage-gated Na+
30

With [3H]NE were determined using rnodi?cations of a

35

L-ascorbic acid and 4.0 rnM disodiurn ethylenediarninetet
raacetate; pH 7.4, and saturated With 95% O2/5% CO2) in a
40

containing 0.1 MM [3H]DA (3,4-[7-3H]
dihydroXyphenylethylarnine; speci?c activity 28 Ci/rnMol)

aliquot part Was superfused With nicotine (1 pM) to deter

activity 14.4 Ci/rnMol), respectively, for an additional 30
45

pargyline (10 pM) and nornifensine (10 pL) or pargyline and

the art, it is not desired to limit the invention to the eXact

desiprarnine (10 pL) in experiments assessing [3H]DA and

construction and operation shoWn and described, and
accordingly, all suitable rnodi?cations and equivalence
thereof may be resorted to, falling Within the scope of the

[3H]NE over?oW, respectively. After 60 min of superfusion,
three 5-rnin samples (5 rnL) Were collected to determine
basal [3H]out?oW. After collection of the third basal sarnple,

invention claimed.

slices from an individual rat Were superfused in the absence
or presence of a single concentration of analog, which

References
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Alkaloid effects on [3H]over?oW from rat striatal slices

preloaded With [3H]DA and hippocarnpal slices preloaded

synaptosornes onto glass ?ber ?lters (6 mm; Type A/E,
Gelrnan Sciences, Ann Arbor, Mich.) under gentle vacuurn
(0.2 atrn), folloWed by three Washes With superfusion buffer
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liquid scintillation spectroscopy.
EXAMPLE 6

rnM MgSO4, 20 rnM ot-D-glucose; pH 7.5) containing 4 pCi
of 86Rb". 86Rb+ uptake was terminated by ?ltration of the

Was subsequently Washed 3 times With 4 rnL ice-cold Kreb’s

buffer containing catechol (1 rnM). Filters Were previously

was homogenized and centrifuged at I1000><g for 10 min at
4° C. The supernatant fraction Was centrifuged at 12,000><g
for 20 min at 4° C. to obtain the synaptosornal fraction.
Synaptosornes Were incubated for 30 min in 35 ML of uptake
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2. The method of claim 1, Wherein R1 is methyl or ethyl.
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CH3

5. The method of claim 1, Wherein the 2,6-substituted
piperidino compound or pharmaceutically effective salt
thereof is trans-2,6-di-trans-styrlpiperidine having the fol

loWing formula (II):

Teng L. H. et a1, “Lobeline displaces [3H]

dihydrotetrabenaZine binding and releases [3H]dopamine
from rat sriatal synaptic vesicles,” J. Neurochem, 1998; 71:
258—265.
What is claimed is:
1. A method of treating an individual for dependence on
or WithdraWal from a drug of abuse, for an eating disorder
or for a CNS disease or pathology, comprising the step of
administering to the individual an effective amount of a

CH3

6. The method of claim 1 Wherein said drug of abuse is

2,6-substituted piperidino compound and pharmaceutically 65 selected from the group consisting of cocaine, amphetamine,
caffeine, nicotine, phencyclidine, opiates, barbiturates,
effective salts thereof, including resolved diasteriomers,
enantiomers thereof, of the formula (I):

benZodiaZepines, canabinoids, hallucinogens and alcohol.
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thereof is administered subcutaneously, intramuscularly,

7. The method of claim 1 wherein in said CNS disease or

pathology is selected from the group consisting of cognitive

intravenously, transdermally, orally, intranasally, intrapul

disorders, brain trauma, memory loss, psychosis, depression,

monary or rectally.

sleep disorders, obsessive compulsive disorders, panic
disorders, myasthenia gravis, Parkinson’s disease, AlZhe

9. The method of claim 1 Wherein said 2,6-substituted

piperidino compound or pharmaceutically effective salt
thereof inhibits release, uptake and storage of DA, NE and

imer’s disease, schiZophrenia, Tourette’s syndrome, Hun
tington’s disease, attention de?cit disorder, hyperkinetic
syndrome, chronic nervous exhaustion, narcolepsy, motion
sickness and the control of pain.
8. The method of claim 1 Wherein said 2,6-substituted
piperidino compound or pharmaceutically effective salt

5-HT by cells of the central nervous system of the indi
vidual.
10
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